Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study
Open Access
- 1 August 2019
- journal article
- research article
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 11, 769-780
Abstract
Background: Treatment of acute myeloid leukemia (AML) is widely centralized. Longer distances to a specialized treatment center may affect patients’ access to curative-intended treatment. Especially during outpatient treatment, distance may also affect survival. Methods and patients: The authors conducted a national population-based cohort study including all AML patients diagnosed in Denmark between 2000 and 2014. We investigated effects of distance (100) to the nearest specialized treatment facility on the probability of receiving intensive chemotherapy, HSCT, and achieving a complete remission (CR) using logistic regression analysis (odds ratios; ORs). For overall survival, we used Cox proportional hazards regression (hazard ratios [HRs]) and adjusted (a) for relevant baseline characteristics. Results: Of 2,992 patients (median age=68.5 years), 53% received intensive chemotherapy and 12% received low-dose chemotherapy outpatient regimens. The median distance to a specialized treatment center was 40 km (interquartile range=10–77 km). No impact of distance to specialized treatment centers was seen on the probability of receiving intensive chemotherapy (10–25 km, aOR=1.1 (CI=0.7–1.7), 25–50 km, aOR=1.1 (CI=0.7–1.7), 50–100 km, aOR=1.3 (CI=0.9–1.9), and >100 km, aOR=1.4 [CI=0.9–2.2]). Overall survival in patients regardless of therapy (100 km, aOR=1.0 [CI=0.9–1.2]), in intensive therapy patients, or in patients’ choice of post-remission was not affected by distance to specialized treatment center. Distance to a transplant center also did not affect the probability of HSCT or survival post-HSCT. Conclusion: In Denmark, distance to a specialized treatment facility offering remission-induction chemotherapy and HSCT does not negatively affect access to curative-indented therapy, treatment-response, or survival in AML patients.Keywords
This publication has 28 references indexed in Scilit:
- Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based studyBlood, 2018
- Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort StudyJournal of Clinical Oncology, 2017
- Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic reviewBMJ Open, 2016
- The Danish National Acute Leukemia RegistryClinical Epidemiology, 2016
- Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort studyBlood, 2015
- Danish registers on personal labour market affiliationScandinavian Journal of Public Health, 2011
- Imputing missing covariate values for the Cox modelStatistics in Medicine, 2009
- Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemiaLeukemia Research, 2008
- Hospital and Physician Volume or Specialization and Outcomes in Cancer Treatment: Importance in Quality of Cancer CareJournal of Clinical Oncology, 2000
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982